Reuters logo
BRIEF-Novartis says RTH258 met endpoints in late-stage trials
2017年6月20日 / 凌晨5点20分 / 3 个月前

BRIEF-Novartis says RTH258 met endpoints in late-stage trials

June 20 (Reuters) - Novartis AG

* Novartis says rth258 (brolucizumab) demonstrates robust visual gains in namd patients with a majority on a 12-week injection interval

* Says 57% and 52% of patients receiving rth258 6 mg in respective trials were maintained exclusively on a q12w interval immediately following loading phase and continuing through week 48

* Says rth258 (brolucizumab) 6 mg met primary and key secondary endpoints in two phase iii studies, hawk and harrier

* Says rth258 3 mg, evaluated in hawk, also met these endpoints Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below